Immunocore PLC - IMCR Net earnings per share for the last four quarters

Official company branding of Immunocore PLC (IMCR)

The success of Immunocore Holdings plc (IMCR) is based on the global sales of Kimmtrak for ocular melanoma. This YoY ttm EPS chart clearly demonstrates market expectations, where the value of 0.00 expresses the metric level. Growth is driven by unique TCR technologies and interest from pharma behemoths. The company's strategy relies on the expansion of its innovative platform to combat solid tumors.

Immunocore (IMCR) Earnings per share for the last twelve months: for the period 02/11/2024 - 11/18/2026

IMCR (Immunocore): analytical breakdowns and indicator data

Initial company analysis:IMCR, Immunocore PLC
Mass-produced product of immunocore.com

To minimize investment risks, it is necessary to assess the stability of profit generation by filtering revenue volatility. This indicator measures the percentage change in net income per share over the trailing twelve months (TTM) relative to the previous year, while the history of the net income per share YoY TTM growth rate reflects the commercial success of Kimmtrak and the effectiveness of new clinical phases at Immunocore Holdings plc (IMCR).

Direct competitors

Earnings per share for the trailing year IBRX (ImmunityBio)|JANX: Net earnings per share (EPS TTM)|RCUS - Net earnings per share for the last four quarters|Earnings per share for the last twelve months zymeworks.com|Net earnings per share for the last 12 months tangotx.com (TNGX)|Earnings per share for the last twelve months Iovance Biotherapeutics Inc (IOVA)|Net earnings per share for the last 12 months Immatics Corp IMTX|Xencor Inc - Net earnings per share for the last 12 months|Net earnings per share (EPS TTM) Compass Therapeutics Corp CMPX|REPL - Earnings per share for the last twelve months|LYEL (lyell.com) - Earnings per share for the last 12 months|Innate Pharma S.A (IPHA) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Pyxis Oncology, Inc. (PYXS)|Net earnings per share for the last 12 months CGEN|IOBT - Net earnings per share for the trailing year|Net earnings per share for the last 12 months STRO (Sutro Bio)|Earnings per share for the last four quarters INKT|Net earnings per share (EPS TTM) HOWL (Werewolf Therapeutics)|Earnings per share for the trailing year IMMX|alxoncology.com - Net earnings per share (EPS TTM)|Earnings per share for the trailing year CUE (Cue Biopharma)|PDS Biotechnology Corp (PDSB) - Earnings per share for the last twelve months|Sonnet BioTherapeutics Holdings, Inc. - Earnings per share for the trailing year|MAIA (MAIABiotech.com) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Liminatus Pharma Inc.|Earnings per share for the last twelve months lavatherapeutics.com (LVTX)|NXTC: Earnings per one share for the last 12 months|Leap Therapeutics - Net earnings per share for the last 12 months|Intensity Tx (INTS) - Net earnings per one share for the last twelve months|SNSE - Earnings per share for the last twelve months|Theriva Biologics - Earnings per share for the last four quarters|Gritstone Bio (GRTS) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Kineta, Inc. (KA)|Net earnings per share for the last 12 months NEXI|TSBX: Earnings per share for the trailing year|Net earnings per share (EPS TTM) VCNX|HARP: Earnings per one share for the last 12 months